论文部分内容阅读
为探讨骨肉瘤中ｐ１６和Ｒｂ蛋白的表达及其相关性，采用免疫组化ＡＢＣ法，对３２例骨肉瘤手术标本使用抗ｐ１６和Ｒｂ蛋白抗体进行检测。结果显示，ｐ１６和Ｒｂ蛋白阳性表达分别为３７．５％（１２／３２）和５６．３％（１８／３２）。在１２例Ｒｂ蛋白阳性或强阳性表达的骨肉瘤中，ｐ１６蛋白表达阴性或弱阳性表达８例（６６．７％）；相反，在１０例Ｒｂ蛋白阴性或弱阳性表达的骨肉瘤中，ｐ１６蛋白阳性或强阳性表达６例（６０．０％）。结果表明：ｐ１６和Ｒｂ蛋白参与骨肉瘤细胞的增殖过程并与骨肉瘤的进展和预后有关；ｐ１６和Ｒｂ蛋白之间阳性表达的相互抑制，可能是判断骨肉瘤恶性程度的标志之一。
In order to investigate the expression of p16 and Rb proteins in osteosarcoma and their correlation, anti-p16 and Rb protein antibodies were detected in 32 surgical specimens of osteosarcoma using immunohistochemical ABC method. The results showed that the positive expression of p16 and Rb proteins were 37.5% (12/32) and 56.3% (18/32), respectively. In 12 cases of osteosarcoma with positive or strong Rb protein expression, p16 protein expression was negative or weakly positive in 8 cases (66.7%); in contrast, in 10 cases of osteosarcoma with negative or weakly positive Rb protein expression, p16 Protein positive or strongly positive expression in 6 cases (60.0%). The results show that p16 and Rb proteins are involved in the proliferation of osteosarcoma cells and are related to the progression and prognosis of osteosarcoma. The mutual inhibition of positive expression of p16 and Rb proteins may be one of the indicators of malignancy of osteosarcoma.